Lipidomics: Potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Lipidomics has developed rapidly over the past decade to the point where clinical application may soon be possible. Developments including high throughput technologies enable the simultaneous quantification of several hundred lipid species, thereby providing a global assessment of lipid metabolism. Given the key role of lipids in the pathophysiology of diabetes and cardiovascular disease, lipidomics has the potential to:Significantly improve prediction of future disease risk,Inform on mechanisms of disease pathogenesis,Identify patient groups responsive to particular therapies andMore closely monitor response to therapy. Lipidomic analyses of both whole plasma and lipoprotein subfractions are integral to the current initiative to understand the relationships between lipoprotein composition and function and how these are affected by disease and treatment. This approach will not only aid in appropriate targeting of existing lipid lowering therapies such as statins and fibrates, but will be important in unravelling the controversies surrounding HDL-based therapies which have failed in clinical trials to date. The ultimate utility of lipidomics to clinical practice will depend firstly on the ability of risk prediction models incorporating lipidomic parameters to significantly improve upon conventional clinical risk markers in predicting future disease risk. Secondly, for widespread application, lipidomic-based measurements must be practical and accessible through standard pathology laboratories. This review will cover developments in lipidomics including methodology, bioinformatics/statistics, insights into disease pathophysiology, the effect of therapeutic interventions, the role of large clinical outcome trials in validating lipidomic approaches to patient management and potential applications in clinical practice.

Original languageEnglish
Pages (from-to)12-23
Number of pages12
JournalPharmacology and Therapeutics
Volume143
Issue number1
DOIs
Publication statusPublished - 2014
Externally publishedYes

Keywords

  • Bioinformatics
  • Cardiovascular disease
  • Diabetes
  • Lipid metabolism
  • Risk assessment
  • Therapeutic monitoring

Cite this

@article{4118528d8e744158af51288b9ea5a429,
title = "Lipidomics: Potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease",
abstract = "Lipidomics has developed rapidly over the past decade to the point where clinical application may soon be possible. Developments including high throughput technologies enable the simultaneous quantification of several hundred lipid species, thereby providing a global assessment of lipid metabolism. Given the key role of lipids in the pathophysiology of diabetes and cardiovascular disease, lipidomics has the potential to:Significantly improve prediction of future disease risk,Inform on mechanisms of disease pathogenesis,Identify patient groups responsive to particular therapies andMore closely monitor response to therapy. Lipidomic analyses of both whole plasma and lipoprotein subfractions are integral to the current initiative to understand the relationships between lipoprotein composition and function and how these are affected by disease and treatment. This approach will not only aid in appropriate targeting of existing lipid lowering therapies such as statins and fibrates, but will be important in unravelling the controversies surrounding HDL-based therapies which have failed in clinical trials to date. The ultimate utility of lipidomics to clinical practice will depend firstly on the ability of risk prediction models incorporating lipidomic parameters to significantly improve upon conventional clinical risk markers in predicting future disease risk. Secondly, for widespread application, lipidomic-based measurements must be practical and accessible through standard pathology laboratories. This review will cover developments in lipidomics including methodology, bioinformatics/statistics, insights into disease pathophysiology, the effect of therapeutic interventions, the role of large clinical outcome trials in validating lipidomic approaches to patient management and potential applications in clinical practice.",
keywords = "Bioinformatics, Cardiovascular disease, Diabetes, Lipid metabolism, Risk assessment, Therapeutic monitoring",
author = "Meikle, {Peter J.} and Gerard Wong and Barlow, {Christopher K.} and Kingwell, {Bronwyn A.}",
year = "2014",
doi = "10.1016/j.pharmthera.2014.02.001",
language = "English",
volume = "143",
pages = "12--23",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier",
number = "1",

}

Lipidomics : Potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. / Meikle, Peter J.; Wong, Gerard; Barlow, Christopher K.; Kingwell, Bronwyn A.

In: Pharmacology and Therapeutics, Vol. 143, No. 1, 2014, p. 12-23.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Lipidomics

T2 - Potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease

AU - Meikle, Peter J.

AU - Wong, Gerard

AU - Barlow, Christopher K.

AU - Kingwell, Bronwyn A.

PY - 2014

Y1 - 2014

N2 - Lipidomics has developed rapidly over the past decade to the point where clinical application may soon be possible. Developments including high throughput technologies enable the simultaneous quantification of several hundred lipid species, thereby providing a global assessment of lipid metabolism. Given the key role of lipids in the pathophysiology of diabetes and cardiovascular disease, lipidomics has the potential to:Significantly improve prediction of future disease risk,Inform on mechanisms of disease pathogenesis,Identify patient groups responsive to particular therapies andMore closely monitor response to therapy. Lipidomic analyses of both whole plasma and lipoprotein subfractions are integral to the current initiative to understand the relationships between lipoprotein composition and function and how these are affected by disease and treatment. This approach will not only aid in appropriate targeting of existing lipid lowering therapies such as statins and fibrates, but will be important in unravelling the controversies surrounding HDL-based therapies which have failed in clinical trials to date. The ultimate utility of lipidomics to clinical practice will depend firstly on the ability of risk prediction models incorporating lipidomic parameters to significantly improve upon conventional clinical risk markers in predicting future disease risk. Secondly, for widespread application, lipidomic-based measurements must be practical and accessible through standard pathology laboratories. This review will cover developments in lipidomics including methodology, bioinformatics/statistics, insights into disease pathophysiology, the effect of therapeutic interventions, the role of large clinical outcome trials in validating lipidomic approaches to patient management and potential applications in clinical practice.

AB - Lipidomics has developed rapidly over the past decade to the point where clinical application may soon be possible. Developments including high throughput technologies enable the simultaneous quantification of several hundred lipid species, thereby providing a global assessment of lipid metabolism. Given the key role of lipids in the pathophysiology of diabetes and cardiovascular disease, lipidomics has the potential to:Significantly improve prediction of future disease risk,Inform on mechanisms of disease pathogenesis,Identify patient groups responsive to particular therapies andMore closely monitor response to therapy. Lipidomic analyses of both whole plasma and lipoprotein subfractions are integral to the current initiative to understand the relationships between lipoprotein composition and function and how these are affected by disease and treatment. This approach will not only aid in appropriate targeting of existing lipid lowering therapies such as statins and fibrates, but will be important in unravelling the controversies surrounding HDL-based therapies which have failed in clinical trials to date. The ultimate utility of lipidomics to clinical practice will depend firstly on the ability of risk prediction models incorporating lipidomic parameters to significantly improve upon conventional clinical risk markers in predicting future disease risk. Secondly, for widespread application, lipidomic-based measurements must be practical and accessible through standard pathology laboratories. This review will cover developments in lipidomics including methodology, bioinformatics/statistics, insights into disease pathophysiology, the effect of therapeutic interventions, the role of large clinical outcome trials in validating lipidomic approaches to patient management and potential applications in clinical practice.

KW - Bioinformatics

KW - Cardiovascular disease

KW - Diabetes

KW - Lipid metabolism

KW - Risk assessment

KW - Therapeutic monitoring

UR - http://www.scopus.com/inward/record.url?scp=84898891503&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2014.02.001

DO - 10.1016/j.pharmthera.2014.02.001

M3 - Article

VL - 143

SP - 12

EP - 23

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 1

ER -